Unknown

Dataset Information

0

Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.


ABSTRACT: Epithelial-to-mesenchymal transition (EMT) is well-known to evoke cancer invasion/metastasis, leading to a high frequency of mortality in patients with metastatic colorectal cancer (mCRC). Protein tyrosine phosphatase (PTPase)-targeted therapy has been identified as a novel cancer therapeutic. Previously, we proved that sorafenib with anti-EMT potency prevents TGF-?1-induced EMT/invasion by directly activating SH2-domain-containing phosphatase 1 (SHP-1)-dependent p-STAT3Tyr705 suppression in hepatocellular carcinoma. Regorafenib has a closely related chemical structure as sorafenib and is approved for the pharmacotherapy of mCRC. Herein, we evaluate whether regorafenib activates PTPase SHP-1 in the same way as sorafenib to abolish EMT-related invasion/metastasis in CRC. Notably, regorafenib exerted potent anti-EMT activity to curb TGF-?1-induced EMT/invasion in vitro as well inhibited lung metastatic outgrowth of SW480 mesenchymal cells in vivo. Mechanistically, regorafenib-enhanced SHP-1 activity significantly impeded TGF-?1-induced EMT/invasion via low p-STAT3Tyr705 level as proved by a SHP-1 inhibitor or siRNA-mediated SHP-1 depletion. Conversely, overexpression of SHP-1 further enhanced the inhibitory effects of regorafenib on TGF-?1-induced p-STAT3Tyr705 and EMT/invasion. Regorafenib directly activates SHP-1 by potently relieving the autoinhibited N-SH2 domain of SHP-1 to inhibit TGF-?1-induced p-STAT3Tyr705 and EMT/invasion. Importantly, the clinical evidence indicated that SHP-1 was positively correlated with E-cadherin and that significantly determined the overall survival of CRC patients. This result further confirms our in vitro data that SHP-1 is a negative regulatory PTPase in EMT regulation and serves as a pharmacological target for mCRC therapy. Collectively, activating PTPase SHP-1 by regorafenib focusing on its anti-EMT activity might be a useful pharmacotherapy for mCRC.

SUBMITTER: Fan LC 

PROVIDER: S-EPMC5325431 | biostudies-other | 2016 Sep

REPOSITORIES: biostudies-other

altmetric image

Publications

Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.

Fan Li-Ching LC   Teng Hao-Wei HW   Shiau Chung-Wai CW   Tai Wei-Tien WT   Hung Man-Hsin MH   Yang Shung-Haur SH   Jiang Jeng-Kai JK   Chen Kuen-Feng KF  

Oncotarget 20160901 39


Epithelial-to-mesenchymal transition (EMT) is well-known to evoke cancer invasion/metastasis, leading to a high frequency of mortality in patients with metastatic colorectal cancer (mCRC). Protein tyrosine phosphatase (PTPase)-targeted therapy has been identified as a novel cancer therapeutic. Previously, we proved that sorafenib with anti-EMT potency prevents TGF-β1-induced EMT/invasion by directly activating SH2-domain-containing phosphatase 1 (SHP-1)-dependent p-STAT3Tyr705 suppression in hep  ...[more]

Similar Datasets

| S-EPMC5836836 | biostudies-other
| S-EPMC4317901 | biostudies-literature
| S-EPMC4385835 | biostudies-other
| S-EPMC7827270 | biostudies-literature
| S-EPMC5041940 | biostudies-literature
| S-EPMC4385937 | biostudies-literature
| S-EPMC5058761 | biostudies-literature
| S-EPMC6741563 | biostudies-literature